



A *Guide* to Prior Authorization Submissions*

*This guide is offered for informational purposes only and is not intended to provide reimbursement or legal advice. The hospital, pharmacy, or healthcare provider is responsible for determining the appropriate codes, coverage, and payment for individual patients. Sobi, Inc. does not guarantee third-party coverage, or payment, or reimbursement for denied claims.



Table of *Contents*

- 03** An Introduction to Submitting a PA for Gamifant® (emapalumab-lzsg)
- 05** The Key Steps in the PA Process
- 06** How to Complete a PA
- 08** A Successful PA Begins With an Accurate and Complete Submission
- 09** Completing the PA Form
- 15** What to Do if a PA Is Denied



An *Introduction* to Submitting a PA for Gamifant® (emapalumab-lzsg)

Your facility may need to obtain prior approval from a health plan before it will cover Gamifant. This request for approval is referred to as a PA, precertification, or coverage determination.

PAs are very common for orphan drugs that treat rare diseases, such as primary hemophagocytic lymphohistiocytosis (HLH), because they enable health plans to ensure that drugs are being used only to treat appropriate patients. For drugs that are used to treat rare diseases, some health plans may require a PA renewal (reauthorization) after a certain period of time. Typically, this is a 3-month or 6-month reauthorization period. It is important to know the renewal period for Gamifant for your patients' health plans. You may need to start the PA process well before the renewal deadline to ensure that your patients can continue coverage.



Gamifant Cares offers access and reimbursement support to help patients access Gamifant. Gamifant Cares provides information regarding patient healthcare coverage options and financial assistance information that may be available to help patients with financial needs. Gamifant Cares can:

- Evaluate a patient's insurance coverage, including benefits investigation, PA, and appeal support
- Provide a Benefit Investigation Summary and, if applicable, any PA requirements
- Identify potential financial assistance options that may be available to help patients with financial needs
- Answer logistical questions and provide information and confirmation around the specialty pharmacy fulfillment process

For more information, call **Gamifant Cares** at **1-833-597-6530** Monday through Friday, 8 AM to 8 PM ET.



HOW THIS GUIDE CAN HELP WITH PA SUBMISSIONS

To help you understand the submission process for a PA for Gamifant® (emapalumab-lzsg), this guide will provide information on



Key steps to a PA submission



Required fields to complete on a PA form



Additional supporting documentation


SITE-OF-CARE RESTRICTIONS FOR INFUSED TREATMENTS

For infused treatments, it is important to determine whether a patient's health plan imposes site-of-care restrictions for infused drugs. These are special restrictions used to determine where the infusion may be administered (eg, a hospital or an outpatient center). Check your patient's health plan to determine if there is a site-of-care restriction.

The Differences Between a PA and a Medical Exception

A medical exception (ME) is a process that allows a physician to prescribe a drug that is not on a health plan's formulary. Typically more complex than PAs, an ME request requires specific documentation, including a Letter of Medical Necessity and more information about the patient's medical history. You may need to complete an ME in addition to a PA in order for your patient to receive Gamifant.

For more information about the ME process and its requirements, refer to [A Guide to Requesting a Medical Exception](#) and the [Sample Letter of Medical Necessity](#).





The *Key Steps* in the PA Process

The next several pages provide you with step-by-step instructions on how to process a PA submission.



STEP 1:
Complete the benefits investigation



STEP 2:
Complete and submit the PA request



STEP 3:
Obtain PA determination



STEP 4:
Review PA approval



How to *Complete* a PA

STEP 1: Complete the benefits investigation



To determine whether your patient has health plan coverage for Gamifant® (emapalumab-lzsg), you will need to complete a benefits investigation. This will help identify

- If a PA is required
- If the health plan has a Gamifant-specific coverage policy
- If the health plan has restrictions on where the drug can be administered
- If any patient cost sharing is required

Tips to Completing a Benefits Investigation

For assistance with the benefits investigation for Gamifant, refer to the [Tips for Completing a Benefits Investigation](#) guide.





How to *Complete* a PA (continued)

STEP 2: Complete and submit the PA request



- Check if there is a specific PA submission process for Gamifant® (emapalumab-lzsg). Some plans use a portal, specific PA form, or call-in process for PA submissions.
- Ensure all required fields of the PA request are filled out. Incomplete and/or incorrect information can cause a PA to be denied.
- Confirm that the PA submission includes the correct site of care where Gamifant will be administered.
- Ensure your PA submission explicitly states the section in the clinical information where your patient fulfills the Gamifant approval criteria. Be specific, as many payers will not identify this information on their own.
 - It is recommended to create a summary document explaining where in the submitted clinical document the payer can find evidence of your patient meeting the required criteria.
- If there is an expedited review/request process, consider submitting your request as urgent for a quicker review/determination.
- Keep a copy of everything your facility submits with the request.

STEP 3: Obtain PA determination



- Follow up with the health plan frequently to ensure that the status of the PA request reflects the need for an urgent review.
- Once the payer makes their determination, ensure you save a copy for your records.

STEP 4: Review PA approval



- Verify that the dates of approval will cover the dates of service for your patient's use.
- Check that the dosage or amount approved in the PA will cover your patient's use.
- Confirm if there is an approved starting dose.
- If a patient is switching from one site of care to another (eg, inpatient to outpatient), a new benefits investigation is needed as the PA process may be different.
- Once you have received the PA decision, ensure that your care team is aware of the outcome.
- If anything should change with the patient, confirm with the payer if another PA is needed.



A Successful PA Begins With an Accurate and Complete Submission

PA submission methods vary by health plan and may require more documentation than what is included on the sample in this guide. Please contact the patient's insurance to obtain their specific PA submission process for Gamifant® (emapalumab-lzsg).

The references to this sample form are intended to help serve as a guide to completing a PA form.

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legibly.

Section A: Requestor Information

First Name: _____ Last Name: _____
Phone: _____ Fax: _____ E-mail: _____

Section B: Patient Information

First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____

Is the requested medication **NEW** ☐ or a **CONTINUATION OF THERAPY** ☐? Start Date: ____/____/____

Section C: Insurance Information

Medicaid ID #: _____ Does patient have other coverage? ☐ Yes ☐ No Carrier Name: _____
Group #: _____ If yes, provide ID #: _____ Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information

Physician Name: _____ Specialty: _____
NPI #: _____ OR MA Provider ID #: _____ State License #: _____
Prescriber Address: _____ Suite #: _____
City/State/Zip: _____ Phone: (____) _____ Fax: (____) _____

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10 CODE: _____
Comorbidities: _____

Section F: Product Information

Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Pharmacy Information

Place of Administration: ☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Specialty Office ☐ Retail Pharmacy
Center Name: _____ Phone: _____ Other: _____ Mail Order: _____
Agency Name: _____ Name: _____
☐ Administration (J0900) (CPT) Phone: _____ Fax: _____

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs: _____

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: _____ Date: ____/____/____

SUBMITTING AN ACCURATE AND COMPLETE PA REQUEST IS ESSENTIAL TO HELP GET YOUR PATIENT ON THERAPY SOONER

Since each health plan has its own requirements, it is important to identify the specific documents to submit with your PA request. Providing supplemental documentation may help get the PA approved and get your patient started on treatment as soon as possible.

In general, a health plan may require the following additional items with your PA submission:

- Completed PA form (forms vary by health plan)
- Peer-reviewed literature
- Relevant patient medical history to inform the treatment recommendation



Completing the PA Form

Check with your patient's health plan for their specific PA form.

This part of the brochure provides a section-by-section guide to completing a PA form. The PA form required by each payer may be organized in a different way but the type of information requested on all PA forms is relatively similar. Be sure to complete all sections accurately.

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legible.

Section A: Requestor Information
First Name: _____ Last Name: _____
Phone: _____ Fax: _____ E-mail: _____

Section B: Patient Information
First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____
Is the requested medication **NEW** ☐ or a **CONTINUATION OF THERAPY** ☐? Start Date: ____/____/____

Section C: Insurance Information
Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____ Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information
Physician Name: _____ Specialty: _____
NPI #: _____ OR MA Provider ID #: _____ State License: _____
Prescriber Address: _____ Suite #: _____
City/State/Zip: _____ Phone: () _____ Fax: () _____

Section E: Diagnosis Information
Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10 CODE: _____
Comorbidities: _____

Section F: Product Information
Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Administration Information
Place of Administration: ☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Center Name: _____ ☐ Physician's Office ☐ Retail Pharmacy
☐ Home Infusion Center ☐ Phone: _____ ☐ Specialty Office ☐ Mail Order
☐ Agency Name: _____ Name: _____
☐ Administration code(s) (CPT): _____ Phone: _____ TIN: _____

Section H: Clinical Information
Explanation of why the preferred medication(s) would not meet your patient's needs: _____

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature
Physician Signature: _____ Date: ____/____/____

○ Patient and Insurance Information sections

- Make sure to list the patient's name exactly as it appears on his or her insurance card. It is important to check for possible name changes and make sure all the documents match.
- Please note that in some instances, the patient may have separate medical and pharmacy benefit cards.
 - Some therapies may be covered under the medical benefit (eg, the same card you would use to charge for the office visit); double-check the card.
- Your patient may have more than 1 health plan. Include information for primary, secondary, and if applicable, tertiary plans.
- Include all relevant patient contact information.



Patient and insurance information should be collected during the benefits investigation.

For assistance, refer to the [Tips for Completing a Benefits Investigation](#) guide.



Completing the PA Form (continued)

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legible.

Section A: Requestor Information

First Name: _____ Last Name: _____
Phone: _____ Fax: _____ Email: _____

Section B: Patient Information

First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____
Is the requested medication NEW ☐ or a CONTINUATION OF THERAPY ☐? Start Date: ____/____/____

Section C: Insurance Information

Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information

Physician Name: _____ Secretary: _____
NPI #: _____ OR MA Provider ID #: _____ State License: _____
Prescriber Address: _____ Suite #: _____
City/State/Zip: _____ Phone: () _____ Fax: _____

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10 CODE: _____
Comorbidities: _____

Section F: Product Information

Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Administration Information

Place of Administration: ☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Physician's Office ☐ Retail Pharmacy
Center Name: _____ Phone: _____ Specialty Office ☐ Mail Order
☐ Home Infusion Center ☐ Other ☐ Name: _____
Agency Name: _____ Phone: _____
☐ Administration code(s) (CPT): _____ TSN: _____ Fax: _____

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs: _____

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: _____ Date: ____/____/____

Physician Information section

- Complete the physician information section, which includes the prescribing physician, diagnosis, and product information.
- Be sure to include the NPI number or Medical Assistance Provider ID number, the licensing information, and complete all other fields in this section.



Completing the PA Form (continued)

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legibly.

Section A: Requestor Information

First Name: _____ Last Name: _____
Phone: _____ Fax: _____ E-mail: _____

Section B: Patient Information

First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____

Is the requested medication **NEW** ☐ or a **CONTINUATION OF THERAPY** ☐? Start Date: ____/____/____

Section C: Insurance Information

Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information

Physician Name: _____ Specialty: _____
NPI #: _____ OR MA Provider ID #: _____ State License: _____
Prescriber Address: _____ City/State/Zip: _____ Phone: (____) _____-____ Fax: (____) _____-____

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10-CODE: _____
Comorbidities: _____

Section F: Product Information

Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Administration Information

Place of Administration: ☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Specialty Office ☐ Retail Pharmacy
Center Name: _____ Phone: _____
☐ Home Infusion Center ☐ Other ☐ Mail Order
Agency Name: _____ Name: _____
☐ Administration code(s) (CPT): _____ Phone: _____ Fax: _____

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs:

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: _____ Date: ____/____/____

Diagnosis and Product Information sections

- Provide a detailed diagnosis and ICD-10-CM code so the health plan understands why the medication is being requested.
- Ensure that both the ICD-10-CM code and the language used to describe the diagnosis match the FDA-approved indication for the drug.
- Include the product name Gamifant® (emapalumab-lzsg), dosage, and NDC number.
- If required, include the HCPCS code.

ICD-10-CM Code¹

D76.1

Description

Hemophagocytic
lymphohistiocytosis

NDC Numbers²

NDC 66658-501-01

Containing one 10 mg/2 mL
(5 mg/mL) single-dose vial

NDC 66658-505-01

Containing one 50 mg/10 mL
(5 mg/mL) single-dose vial

NDC 66658-510-01

Containing one 100 mg/20 mL
(5 mg/mL) single-dose vial

HCPCS Code³

J9210

Description

Injection, emapalumab-lzsg,
1 mg

FDA=US Food and Drug Administration; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; NDC=National Drug Code.

For additional codes that may be useful, please see the **Summary of Relevant Codes**.



Completing the PA Form (continued)

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legibly.

Section A: Requestor Information

First Name: Last Name: Phone: Fax: Email:

Section B: Patient Information

First Name: Last Name: Member ID: Address: City: State: Zip: Phone: DOB: Allergies:

Is the requested medication **NEW** or a **CONTINUATION OF THERAPY**? Start Date: / /

Section C: Insurance Information

Member ID #: Does patient have other coverage? ☐ Yes ☐ No
Group #: If yes, provide ID#: Carrier Name:
Insured: Medication: ☐ Yes ☐ No If yes, provide ID #: Medication: ☐ Yes ☐ No If yes, provide ID #:

Section D: Physician Information

Physician Name: Specialty: NPI #: OR MA Provider ID #: State License: Prescriber Address: Suite #: City/State/Zip: Phone: () Fax: ()

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): ICD-10 CODE: Comorbidities:

Section F: Product Information

Medication: Strength: Directions for use:

Section G: Dispensing Provider/Administration Information

Place of Administration:
☐ Hospital ☐ Physician's Office
☐ Outpatient Infusion Center ☐ Specialty Office
☐ Home Infusion Center ☐ Mail Order
☐ Administration (CPT): Agency Name: Name: Phone: TIN: Fax:

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs:

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: Date: / /

Dispensing Provider/Administration Information section

- For the Place of Administration, select the type of facility where Gamifant® (emapalumab-lzsg) will be administered (eg, hospital, outpatient infusion center, physician's office). If the form asks for additional information about the Place of Administration, include the name, tax ID number, NPI, and date of service.
- For the Dispensing Provider/Pharmacy section, indicate if Gamifant will be obtained from the Gamifant specialty distributor, McKesson Plasma and Biologics, or the Gamifant specialty pharmacy, Biologics.



Completing the PA Form (continued)

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legibly.

Section A: Requestor Information

First Name: _____ Last Name: _____
Phone: _____ Fax: _____ Email: _____

Section B: Patient Information

First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____

Is the requested medication **NEW** ☐ or a **CONTINUATION OF THERAPY** ☐? Start Date: ____/____/____

Section C: Insurance Information

Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information

Physician Name: _____ Specialty: _____
NPI #: _____ OR MA Provider ID #: _____ State License: _____
Prescriber Address: _____ Suite #: _____
City/State/Zip: _____ Phone: () _____ Fax: () _____

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10 CODE: _____
Comorbidities: _____

Section F: Product Information

Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Administration Information

Place of Administration:
☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Home Infusion Center ☐ Specialty Office ☐ Retail Pharmacy
Center Name: _____ Phone: _____ Name: _____ Mail Order
Agency Name: _____ Phone: _____ TIN: _____ Fax: _____
☐ Administration code(s) (CPT): _____

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs: _____

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: _____ Date: ____/____/____

Clinical Information section

- Provide a detailed explanation describing why Gamifant® (emapalumab-lzsg) is appropriate for your patient.
- Refer to the **Sample Letter of Medical Necessity** template to help with your explanation. You may need to provide additional documentation, such as the patient's medical history, clinical notes detailing the relevant diagnosis, applicable laboratory results, and peer-reviewed literature.
- Review the insurance plan's specific policy on Gamifant, or if a policy is not available, the Medical Information Checklist.



Completing the PA Form (continued)

Regional Health Plan 123 Park Ave. • Hometown, IA • 55555 | Phone: 1-888-555-1234 Fax: 1-888-555-5678
For Medicare Part B— Fax: 1-888-555-9191

Prior Authorization Request Form

All fields must be completed in their entirety and legible.

Section A: Requestor Information

First Name: _____ Last Name: _____
Phone: _____ Fax: _____ E-mail: _____

Section B: Patient Information

First Name: _____ Last Name: _____ Member ID: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ DOB: _____ Allergies: _____

Is the requested medication **NEW** ☐ or a **CONTINUATION OF THERAPY** ☐? Start Date: ____/____/____

Section C: Insurance Information

Member ID #: _____ Does patient have other coverage? ☐ Yes ☐ No
Group #: _____ If yes, provide ID#: _____ Carrier Name: _____
Insured: _____ Insured: _____
Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ Medicaid: ☐ Yes ☐ No If yes, provide ID #: _____

Section D: Physician Information

Physician Name: _____ Specialty: _____
NPI #: _____ OR MA Provider ID #: _____ State License: _____
Prescriber Address: _____ Suite #: _____
City/State/Zip: _____ Phone: () _____ Fax: () _____

Section E: Diagnosis Information

Diagnosis (Please be specific & provide as much information as possible): _____ ICD-10-CODE: _____
Comorbidities: _____

Section F: Product Information

Medication: _____ Strength: _____
Directions for use: _____

Section G: Dispensing Provider/Administration Information

Place of Administration: ☐ Hospital ☐ Physician's Office ☐ Dispensing Provider/Pharmacy: Patient selected choice
☐ Outpatient Infusion Center ☐ Home Infusion Center ☐ Specialty Office ☐ Retail Pharmacy
Center Name: _____ Phone: _____ Name: _____
Agency Name: _____ Phone: _____ Mail Order
☐ Administration code(s) (CPT): _____ Fax: _____

Section H: Clinical Information

Explanation of why the preferred medication(s) would not meet your patient's needs: _____

Section I: Patient Treatment History

Medications	Strength	Dates of Therapy	Reason for failure/discontinuation

Section J: Physician Signature

Physician Signature: _____ Date: ____/____/____

Patient Treatment History and Physician Signature sections

- List any medications the patient has used for treatment, including any treatments that may be required by the plan before the use of Gamifant® (emapalumab-lzsg). Review the patient's benefits investigation.
- If the request is outside of the health plan's policy, a Letter of Medical Necessity may be required to help the PA process. See the **Sample Letter of Medical Necessity**.
- Ensure that the prescribing physician's signature is on all documentation where required.



What to Do if a PA Is *Denied*

If a PA is denied, determine the reason for the denial. If you cannot determine the denial reason, contact the plan for more information about the denial.

One of the most common reasons a PA is denied is that information is incomplete or inaccurate. In cases where there are mistakes or omissions, resubmit the form.

When a PA is denied, the physician can appeal the decision directly. He or she can call the health plan to have a peer-to-peer discussion with a medical representative at the plan. The physician can explain the patient's background and the reasons for prescribing Gamifant® (emapalumab-lzsg). Refer to the **Guide to Denials and Appeals** for more information.

In the event a peer-to-peer discussion is not an option, you can submit an ME request. Refer to **A Guide to Requesting a Medical Exception**.



Due to the rarity of primary HLH, it is very likely that the prescribing physician will need to have a peer-to-peer discussion with the health plan to explain the disease, the patient's medical history and condition, and the rationale for prescribing Gamifant once the PA is submitted.



Contact **Gamifant Cares** at **1-833-597-6530** for assistance with the PA process.

IMPORTANT INFORMATION: Any coding, coverage, payment, or other information contained herein is gathered from various resources, general in nature, and subject to change without notice. Third-party payment for medical products and services is affected by numerous factors. It is always the provider's responsibility to determine the appropriate healthcare setting and to submit true and correct claims conforming to the requirements of the relevant payer for those products and services rendered. Hospitals and pharmacies (or any other provider submitting a claim) should contact third-party payers for specific information on their coding, coverage, and payment policies. Information and materials provided by Gamifant Cares are to assist providers, but the responsibility to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure remains at all times with the provider and information provided by Gamifant Cares or Sobi, Inc. should in no way be considered a guarantee of coverage or reimbursement for any product or service.

References: **1.** ICD-10-CM code for hemophagocytic lymphohistiocytosis D76.1. Codify by AAPC website. Accessed January 17, 2024. <https://www.aapc.com/codes/icd-10-codes/D76.1> **2.** Gamifant [prescribing information]. Waltham, MA: Sobi, Inc; 2022. **3.** HCPCS Quarterly Update. Centers for Medicare & Medicaid Services website. Accessed January 17, 2024. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update>



Gamifant is a registered trademark, owned by Sobi AG and is marketed by Sobi, Inc.
©2024 Swedish Orphan Biovitrum. All rights reserved. PP-9435 (V4.0) 02/24